{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:10:59Z","timestamp":1781752259791,"version":"3.54.5"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EJR"],"abstract":"<jats:p>Objective: Osteoporosis (OP) can complicate the course of rheumatic musculoskeletal diseases (RMDs)\u00a0and connective tissue diseases (CTDs). Denosumab, a monoclonal antibody against RANK-L, showed beneficial\u00a0effect in rheumatoid arthritis in inhibiting radiographic progression and erosive burden. We tested\u00a0the efficacy, safety, and persistence on the treatment of the combination of biologic disease-modifying\u00a0antirheumatic drugs (bDMARDs)\/denosumab versus bDMARD in patients with RMD and CTD.\n\nMethods: This is a retrospective evaluation of a single center, including patients with RMD\/CTD\u00a0(including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, systemic sclerosis, and\u00a0overlap syndromes) treatment with bDMARD\/denosumab, compared to age, gender, disease,\u00a0bDMARD, and conventional synthetic disease-modifying antirheumatic drugs-matched controls.\n\nResults: Twenty-eight bDMARD\/denosumab patients and 49 bDMARD patients were eligible. Despite\u00a0a statistically significant difference during the first-year efficacy (due to the different baseline timepoint),\u00a0there was no difference in the efficacy profile in the second year of treatment and in the safety\u00a0profile (including local, systemic, and serious adverse events). Moreover, no statistically significant\u00a0difference\u00a0in the persistence of bDMARD treatment over 2 years of evaluation was found. The combination\u00a0of bDMARD and denosumab was not an independent predictor of disease flare or bDMARD\u00a0treatment withdrawal.\n\nConclusion: The combination of bDMARD and denosumab does not alter the efficacy and the safety\u00a0profile of the bDMARD in patients with RMD\/CTD. Future studies verifying the radiological disease\u00a0inhibition could support denosumab use in RMD\/CTD other than rheumatoid arthritis, when\u00a0complicated\u00a0by OP.\n\nCite this article as: Bruni C, Cigolini C,\u00a0Tesei G, et al. Combination of denosumab\u00a0and biologic DMARDs in inflammatory\u00a0muscle-skeletal diseases and connective\u00a0tissue diseases. Eur J Rheumatol.\u00a02021;8(4):190-195.\n<\/jats:p>","DOI":"10.5152\/eurjrheum.2020.21162","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T05:22:50Z","timestamp":1637558570000},"page":"190-195","source":"Crossref","is-referenced-by-count":4,"title":["Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases"],"prefix":"10.5152","volume":"8","author":[{"given":"Cosimo","family":"Bruni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Cigolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tesei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cometi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Nacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bellando-Randone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3111","published-online":{"date-parts":[[2021,10,1]]},"container-title":["European Journal of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/download\/490\/490","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:12:41Z","timestamp":1753773161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/view\/490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,11,10]]}},"URL":"https:\/\/doi.org\/10.5152\/eurjrheum.2020.21162","relation":{},"ISSN":["2148-4279"],"issn-type":[{"value":"2148-4279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]}}}